by Leptospirosis is a bacterial infection caused by Leptospira interrogans, which commonly affects cattle, pigs, and dogs. The infection in humans occurs through contact with urine of infected animals or contaminated water or soil. Symptoms include fever, muscle pains, jaundice, and respiratory distress.
The global Leptospirosis Market is estimated to be valued at US$ 496.8 Mn in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
According to the World Health Organization (WHO), leptospirosis is one of the most widespread zoonoses (diseases that can spread between animals and humans) globally. It is estimated that over one million cases of leptospirosis occur annually worldwide, majority of which go undiagnosed and unreported. Countries with warm climates tend to report more cases. With change in climate leading to more favorable conditions for bacteria to survive and spread, incidence of leptospirosis has increased across various regions worldwide. This rising disease prevalence has augmented demand for diagnosis and treatment solutions for leptospirosis, thereby propelling the market growth.
SWOT Analysis
Strength: The increasing prevalence of leptospirosis disease is driving the market growth. Government initiatives and funds for R&D activities related to vaccines and therapeutics is further fuelling the market.
Weakness: Lack of awareness about leptospirosis disease especially in developing nations poses a challenge. High cost associated with vaccines and therapeutics is also a concern.
Opportunity: Development of novel treatment options and vaccines presents lucrative opportunities. Growing healthcare infrastructure in emerging markets offers potential for market expansion.
Threats: Stringent regulatory framework for approval of drugs and biosimilar products adds to development challenges. Patent expiration of blockbuster drugs also threatens market growth.
Key Takeaways
The Global Leptospirosis Market Size is expected to witness high growth at a CAGR of 5.8% during the forecast period of 2023 to 2030. The market size is estimated to reach US$ 830.3 Mn by 2030.
Regional analysis
North America dominated the global leptospirosis market in 2023. This is attributed to advanced healthcare system, growing R&D investments by key players, and increasing prevalence of the disease. Asia Pacific region is expected to witness fastest growth during the forecast period owing to large patient pool, growing awareness about disease management, and improving healthcare infrastructure in emerging economies.
Key players
Key players operating in the leptospirosis market are USAntibiotics, Dr. Reddy’s Laboratories Ltd., Century Pharmaceuticals Ltd., Mayne Pharma Group Limited, Sun Pharmaceutical Industries, Inc., Ralington Pharma, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sandoz International GmbH, ISKON REMEDIES & GMT, Haustus Biotech Pvt. Ltd., and Aden Healthcare. These companies focus on development of advanced therapeutics and expanding their regional presence through collaboration and acquisitions.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
